NSE: LALPATHLAB | BSE: 539524

Mid-range Performer

Download real time

1376.20 -1.00 (-0.07%)

365.5K NSE+BSE Volume

NSE 21 Jan, 2026 12:48 PM (IST)

23,058.4

Market Cap

Market Runner Up

Beta 1Year

Very Low volatility

Board Meeting

The next board meeting for Dr. Lal Pathlabs is on 30 Jan 2026 for the purpose of Quarterly Results & Others See details

Dr. Lal Pathlabs Ltd. share price target and research reports

Latest analyst research reports with target prices and PDF download for LALPATHLAB, BSE:539524 Dr. Lal Pathlabs Ltd.

Search Inside the pdf :

Dr. Lal Pathlabs Ltd.

02 Sep 2025

1376.20

-0.07%

DR. LAL PATHLABS LIMITED

Hold: Dr. Lal Pathlabs Ltd.

Target

Geojit BNP Paribas

*over or under performance to benchmark index Dr Lal PathLabs Ltd (DLPL) provides diagnostic tests and services globally. As of December 2024, DLPL had 280 clinical laboratories, including a national reference lab...

Number of FII/FPI investors decreased from 391 to 378 in Dec 2025 qtr

Dr. Lal Pathlabs Ltd.

20 Jul 2025, 12:00AM

1376.20

-0.07%

FY25 AR: Stable outlook despite leadership transition

Buy: Dr. Lal Pathlabs Ltd.

Emkay

Following the slump in FY23, DLPL has registered revenue/EBITDA/PAT CAGR of 10%/19%/43%, respectively, over the last two years.

Number of FII/FPI investors decreased from 391 to 378 in Dec 2025 qtr

Dr. Lal Pathlabs Ltd.

12 May 2025

1376.20

-0.07%

DR. LAL PATH LABS LTD.

Buy: Dr. Lal Pathlabs Ltd.

FundsIndia

Number of FII/FPI investors decreased from 391 to 378 in Dec 2025 qtr

Dr. Lal Pathlabs Ltd.

26 Apr 2025

1376.20

-0.07%

Decent quarter, limited headroom for margins expansion

Hold: Dr. Lal Pathlabs Ltd.

Target

ICICI Securities Limited

Dr Lal PathLabs’ (Dr Lal) Q4FY25 results were slightly better than our expectation. Outperformance was driven by higher sample volumes (up 9.5% YoY) and realisation improvement.

Dr. Lal Pathlabs Ltd. is trading below all available SMAs

Dr. Lal Pathlabs Ltd.

26 Apr 2025

1376.20

-0.07%

Steady quarter; encouraging outlook

Buy: Dr. Lal Pathlabs Ltd.

Target

Emkay

DLPL reported a steady Q4, with EBITDA beating street/our estimates by 6% and adj PAT improving 34% on YoY basis. Strong performance in core markets (Delhi NCR), buoyed by network expansion, offset the persistent muted performance of Suburban (mid-single digit revenue growth).

Number of FII/FPI investors decreased from 391 to 378 in Dec 2025 qtr

Dr. Lal Pathlabs Ltd.

14 Feb 2025

1376.20

-0.07%

DR. LAL PATHLABS LIMITED

Accumulate: Dr. Lal Pathlabs Ltd.

Target

Geojit BNP Paribas

Dr. Lal Pathlabs Ltd. is trading below all available SMAs

Dr. Lal Pathlabs Ltd.

13 Jan 2025

1376.20

-0.07%

DR. LAL PATHLABS LTD.

Sell: Dr. Lal Pathlabs Ltd.

Ventura

Elevated Valuations Dampen Strong Fundamentals

Number of FII/FPI investors decreased from 391 to 378 in Dec 2025 qtr

Dr. Lal Pathlabs Ltd.

24 Oct 2024

1376.20

-0.07%

Growth moderates; near term green shoots unlikely

Hold: Dr. Lal Pathlabs Ltd.

Target

ICICI Securities Limited

Dr Lal PathLabs’ (Dr Lal) Q2FY25 revenue growth of 9.8% YoY was lower than our expectation, though its better EBITDA margin of 30.7% was a surprise.

Number of FII/FPI investors decreased from 391 to 378 in Dec 2025 qtr

Dr. Lal Pathlabs Ltd.

22 Aug 2024

1376.20

-0.07%

DR. LAL PATHLABS LIMITED

Hold: Dr. Lal Pathlabs Ltd.

Recommendation Target

Geojit BNP Paribas

Dr. Lal Pathlabs Ltd. is trading below all available SMAs

Dr. Lal Pathlabs Ltd.

08 Aug 2024

1376.20

-0.07%

Steady quarter; valuation a bit pricey

Hold: Dr. Lal Pathlabs Ltd.

Target

ICICI Securities Limited

Dr Lal PathLabs’ (Dr Lal) Q1FY25 result was in line with our expectations. Growth was driven by better uptick in Swasthfit (up 26.4% YoY) overall sample volume rose 9.3% YoY.

Dr. Lal Pathlabs Ltd. is trading below all available SMAs

Is Dr. Lal Pathlabs Ltd. worth buying?

231 Votes:

Buy 76.19%

Sell 14.72%

Hold 9.09%

RESEARCH REPORTS

Hold SEE REPORTS >

pdf

Buy SEE REPORTS >

pdf